Onexton (clindamycin-benzoyl peroxide 3.75)

Onexton (clindamycin-benzoyl peroxide 3.75) is filed as Topical Anti-Acne. The sections below restate public label fields stored for this profile.

Class
Topical Anti-Acne
Generic name
clindamycin-benzoyl peroxide 3.75
Route
TOPICAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Gel, 1.2%/3.75% Each gram of ONEXTON Gel contains 12 mg (1.2%) clindamycin phosphate, equivalent to 10 mg (1%) clindamycin, and 37.5 mg (3.75%) benzoyl peroxide in a white to off-white, opaque, smooth gel. Gel, 1.2% clindamycin phosphate/3.75% benzoyl peroxide
Generic available
Yes
Manufacturer
Bausch Health US, LLC

Approved uses

1 INDICATIONS AND USAGE ONEXTON ® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ONEXTON Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )

How it works

12.1 Mechanism of Action Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology (12.4) ] . Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS • Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of clindamycin. ONEXTON Gel should be discontinued if significant diarrhea occurs. ( 5.1 ) • Ultraviolet Light and Environmental Exposure: Minimize sun exposure following drug application. ( 5.2 ) 5.1 Colitis Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. If significant diarrhea occurs, ONEXTON Gel should be discontinued. Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death. Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. 5.2 Ultraviolet Light and Environmental Exposure Minimize sun exposure (including use of tanning beds or sun lamps) following drug application. 5.3 Concomitant Topical Medications Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.

Contraindications

4 CONTRAINDICATIONS ONEXTON Gel is contraindicated in: • Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. ( 4.1 ) • Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. ( 4.2 ) 4.1 Hypersensitivity ONEXTON Gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with ONEXTON Gel [see Postmarketing Experience (6.2) ] . 4.2 Colitis/Enteritis ONEXTON Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see Warnings and Precautions (5.1) ] .

Common side effects

Burning sensation (0.4%); Contact dermatitis (0.4%); Pruritus (0.4%); And rash (0.4%)

Adverse reactions

The following adverse reaction is described in more detail in the Warnings and Precautions section of the label: • Colitis [see Warnings and Precautions (5.1) ] .

Dosage and administration

2 DOSAGE AND ADMINISTRATION Before applying ONEXTON Gel, wash the face gently with a mild soap, rinse with warm water, and pat the skin dry. Apply a pea-sized amount of ONEXTON Gel to the face once daily. Avoid the eyes, mouth, mucous membranes, or areas of broken skin. Use of ONEXTON Gel beyond 12 weeks has not been evaluated. ONEXTON Gel is not for oral, ophthalmic, or intravaginal use. • Apply a pea-sized amount of ONEXTON Gel to the face once daily. ( 2 ) • Not for oral, ophthalmic, or intravaginal use. ( 2 )

Drug interactions

7 DRUG INTERACTIONS Avoid using ONEXTON Gel in combination with topical or oral erythromycin-containing products because of its clindamycin component. ( 7.1 ) 7.1 Erythromycin Avoid using ONEXTON Gel in combination with topical or oral erythromycin-containing products due to its clindamycin component. In vitro studies have shown antagonism between erythromycin and clindamycin. The clinical significance of this in vitro antagonism is not known. 7.2 Neuromuscular Blocking Agents Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. ONEXTON Gel should be used with caution in patients receiving such agents.

Common questions

What is Onexton approved to treat?

According to its FDA label, Onexton (clindamycin-benzoyl peroxide 3.75) is approved for: 1 INDICATIONS AND USAGE ONEXTON ® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ONEXTON Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and be… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Onexton?

Onexton (clindamycin-benzoyl peroxide 3.75) belongs to the Topical Anti-Acne class of medications.

What form does Onexton come in?

The FDA label lists Onexton (clindamycin-benzoyl peroxide 3.75) as: 3 DOSAGE FORMS AND STRENGTHS Gel, 1.2%/3.75% Each gram of ONEXTON Gel contains 12 mg (1.2%) clindamycin phosphate, equivalent to 10 mg (1%) clindamycin, and 37.5 mg (3.75%) benzoyl peroxide in a white to off-white, opaque, smooth gel. Gel, 1.2% clindamycin phosphate/3.75% benzoyl peroxide; topical route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Onexton?

Yes. A generic version of Onexton (clindamycin-benzoyl peroxide 3.75) is available in the U.S. Ask your pharmacist about substitution.

Does Onexton have a Boxed Warning?

Our ingest of the FDA label for Onexton (clindamycin-benzoyl peroxide 3.75) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Onexton cost?

Public CMS NADAC pricing for Onexton (clindamycin-benzoyl peroxide 3.75) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Onexton currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Onexton (clindamycin-benzoyl peroxide 3.75) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Onexton approved by the FDA?

The FDA record lists the approval date for Onexton (clindamycin-benzoyl peroxide 3.75) as 2008-10-23.

Who makes Onexton?

The FDA label lists Bausch Health US, LLC as a labeler/manufacturer of Onexton (clindamycin-benzoyl peroxide 3.75). Multiple firms may market generics of the same molecule.

How should Onexton be stored?

The FDA label states: "How Supplied ONEXTON Gel, 1.2%/3.75% is a white to off-white smooth gel supplied as: NDC 0187-3050-50 50 g pump Dispensing Instructions for the Pharmacist • Dispense ONEXTON Gel with a 8-week expiration date. • Specify “…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…